This is further illustrated by the co-administration of an angiotensin-converting enzyme (ACE) inhibitor in hypertension drug therapy to mitigate the peripheral oedema that accompanies calcium channel antagonists due to the venodilation imposed by ACE inhibitors. The gene discussed is ACE; the disease is hypertensive disorder.